FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | IN BENEFICIAL | OWNERSHIP |
|-----------|-------------------|---------------|------------------|

| OMB APP | ROVAL |
|---------------------|-----------|
| OMB Number: | 3235-0287 |
| Estimated average b | ourden |
| houre per reenonee. | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Vogt Frederick G | | | | | <u>IO</u> | 2. Issuer Name and Ticker or Trading Symbol IOVANCE BIOTHERAPEUTICS, INC. [IOVA] | | | | | | | | | | eck all applic | cable) or | g Pers | Person(s) to Issuer 10% Owner | |
|--|--|---------------------------------------|---|---------|---|--|-------|--------------------------|---------------|--|-------|------------------------|--------|--|---|---|---|---|--|--|
| | ANCE BIC | irst) OTHERAPEUTIO ROAD, 4TH FL | 1 | | | 3. Date of Earliest Transaction (Month/Day/Year) 12/02/2024 | | | | | | | | | below) | | Gene | Other (s below) eral Couns | · | |
| (Street) SAN CA (City) | RLOS C | | 94070 (Zip) | | 4. II | | | | | | | | | Line | ndividual or Joint/Group Filing (Check Applicable e) Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| | | Tab | le I - Nor | n-Deriv | ative | e Se | curit | ies Ac | quire | ed, D |)isp | osed o | of, or | r Ber | neficial | y Owned | | | | |
| '''''''' [| | 2. Trans Date (Month/ | n/Day/Year) i | | 2A. Deemed Execution Date, if any (Month/Day/Year) | | Co | Transaction Code (Instr. | | 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5) | | | | 5. Amou Securitie Benefici Owned I Reporte | es ally Following | Form (D) o | n: Direct r Indirect istr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | | | Co | de \ | v | Amount | | (A) or (D) | Price | Transac (Instr. 3 | tion(s) | | | (111501. 4) |
| Common Stock ⁽¹⁾ | | | 12/02 | 2/2024 | | | | 1 | И | | 10,41 | 7 | A | \$0 | 214 | 1,662 | | D | | |
| Common Stock ⁽²⁾ | | 12/02 | 2/2024 | | | | 7 | | 4,420 | 6 | D | \$9.0 | 7 210 | 236(3) | | D | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transactic Date (Month/Day/ | | | 3A. Deemed Execution I if any (Month/Day | Date, 1 | Code (Instr | | n of | | Expir | 6. Date Exercisa Expiration Date (Month/Day/Yea | | of Secur r) Underly | | ecurition erlying vative | J Security | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | Ow For Dire or I (I) (| 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Co | Code | v | (A) | (D) | Date Exerc | isable | | xpiration ate | Title | | Amount or Number of Shares | ber | | | | |
| Restricted Stock Units | (4) | 12/02/2024 | | | M | | | 10,417 | (| 5) | | (5) | Com | nmon ock | 10,417 | \$0.00 | 52,087 | (6) | D | |

Explanation of Responses:

- 1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
- 2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
- 3. Represents common stock remaining after deducting the common stock withheld for taxes.
- 4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- 5. The remaining RSUs will vest in equal quarterly installments.
- 6. Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person.

/s/ Frederick G. Vogt

12/04/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.